The Company''s Wholly owned subsidiary, IBL Investment Limited, has received approval from SEBI for Category II Alternate Investment Fund Registration
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Indrayani Biotech's wholly-owned subsidiary, IBL Investments Limited, has received SEBI approval to register 'IBL Investment Trust' as a Category II Alternative Investment Fund (AIF). The registration number IN/AIF2/25-26/1900 is effective from 15th September 2025 and is perpetual in nature. Category II AIFs are permitted to invest in various asset classes including private equity, debt, and structured products, but cannot accept investments below Rs. 1 crore. This marks the company's entry into the registered fund management space via its subsidiary.
Positive development as it opens a new business vertical in fund management through the subsidiary, potentially diversifying revenue streams. However, near-term financial impact is unclear and the AIF business may take time to scale and contribute meaningfully to earnings.